Epidemiological Features of HPV-Associated Cancer in situ of Various Localization

Relevance. In Russia and abroad, the incidence of cancer in situ (CIS) of the breast and cervix is most widely represented, the epidemiological features of this neoplasia of other localizations have not been studied sufficiently. Among them, a significant place is occupied by a group of malignant neoplasms in situ associated with the human papillomavirus (HPV), which have common etiopathogenetic mechanisms of development.
The aim of the study was to determine the structure, as well as the incidence and mortality rates from HPV-associated cancer in situ among the population of St. Petersburg.
Material and methods. The research materials included cases of cancer in situ of the oral cavity, pharynx, larynx, anal canal, vulva, vagina, cervix and penis in St. Petersburg in the period 2001 –2023. The calculation of the indicators was carried out according to the data of form No. 7 «Information on malignant neoplasms» and archival materials of the Population Cancer Registry of St. Petersburg. The analysis included 1952 cases of the disease and 50 deaths from malignant neoplasms, initially registered as cancer in situ. Research methods: retrospective epidemiological analysis and statistical methods.
The results of the study. In the structure of in situ cancer associated with HPV, among the male population, the largest proportion was occupied by CIS of the larynx and penis (36.4% each), among the female population – cervix (94.9%). The average long-term incidence of cancer in situ of the oral cavity, pharynx, larynx, anal canal, vagina and penis was less than 0.1 per 100 thousand of the population with the maximum incidence in the age group of 50-69 years. From 2001 to 2023 in St. Petersburg, the incidence of cervical CIS decreased significantly from 6.86 to 1.17 per 100 thousand. the female population (p = 0.001), while since 2004, the highest incidence rate has been recorded annually in the 30 –39 age group. From 2001 to 2023, 11 cases (31.4% of all CIS localities) among males and 39 cases (27.7% of all CIS cases) among the female population became the cause of death from HPV-associated ZNO, initially registered as cancer in situ of the corresponding localizations.
Conclusion. As a result of the study, epidemiological features of morbidity and mortality from HPVassociated cancer in situ of various localization in the conditions of St. Petersburg were established.

1. Wild CP, Weiderpass E, Stewart BW. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. 2020. Available at: http://publications.iarc.fr/586. Accessed: 3 Feb 2024.

2. Cancer Research UK. In situ cervical carcinoma incidence statistics. 2020. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statisticsby-cancer-type/cervical-cancer/incidence-in-situ#heading-Zero. Accessed: 4 Apr 2024.

3. Garelik TM, Naumov IA. Study of the clinical and epidemiological situation for the detection of cervical cancer in the Grodno region as an element of the development of secondary prevention measures. Modern problems of hygiene, radiation and environmental medicine. 2017; 7:33–44. (In Russ).

4. Kaprin AD, Starinskii VV, Shakhzadova АО. Malignant neoplasms in Russia in 2022 (morbidity and mortality). M.: P. Hertsen MORI - branch of the FSBI NMRRC of the Ministry of Health of the Russian Federation. 2023. (In Russ).

5. Khorov OG, Nikita EI, Plavsky DM. Eurasian. Differential diagnosis of obligate diseases of the larynx. Eurasian Journal of Oncology. 2019; 7(3):304–312. (In Russ).

6. Stepanova YuE, Gotovyakhina TV, Koren EE, et al. Endoscopic diagnosis of precancerous diseases and laryngeal cancer in the practice of a phoniatrician. Russian otorhinolaryngology. 2017;6(91):128–34. (In Russ).

7. Markou K, Christoforidou A, Karasmanis I, et al. Laryngeal cancer: epidemiological data from Νorthern Greece and review of the literature. Hippokratia. 2013;17(4):313–8.

8. Nelson RA, Levine AM, Bernstein L, et al. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. 2013;31(12):1569–75. doi: 10.1200/JCO.2012.45.2524.

9. Ho VKY, Deijen CL, Hemmes B, et al. Trends in epidemiology and primary treatment of anal squamous cell carcinoma in the Netherlands (1990-2021). Int J Cancer. 2024;154(9):1569–78. doi: 10.1002/ijc.34811.

10. Bucchi L, Pizzato M, Rosso S, et al. New Insights into the Epidemiology of Vulvar Cancer: Systematic Literature Review for an Update of Incidence and Risk Factors. Cancers (Basel). 2022;14(2):389. doi: 10.3390/cancers14020389.

11. Oonk MHM, Planchamp F, Baldwin P, et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023. Int J Gynecol Cancer. 2023;33(7):1023–43. doi: 10.1136/ijgc-2023-004486.

12. Judson PL, Habermann EB, Baxter NN, et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstetrics and Gynecology. 2006;107(5):1018–22. doi: 10.1097/01.AOG.0000210268.57527.a1.

13. Gadducci A, Fabrini MG, Lanfredini N, et al. Squamous Cell Carcinoma of the Vagina: Natural History, Treatment Modalities and Prognostic Factors. Crit Rev Oncol Hematol. 2015;93:211–24. doi: 10.1016/j.critrevonc.2014.09.002.

14. IARC, Urinary and Male Genital Tumours. WHO Classification of Tumours, 5th Edn. Vol. 8. 2022. Available at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Urinary-And-Male-Genital-Tumours-2022. Accessed: 18 Apr 2024.

15. Muravyeva ES, Bogdanova NA. The experience of diagnosis and treatment of Keira’s erythroplasia. Tverskoy medical Journal. 2023;6:25–28. (In Russ).

16. Giona S, Barber N, Ali A, editors. The Epidemiology of Penile Cancer. Urologic Cancers [Internet]. Brisbane (AU): Exon Publications. 2022;11. doi: 10.36255/exon-publicationsurologic-cancers-epidemiology-penile-cancer.

17. The authors, et al. 2022.

18. The authors, et al. 2023.

19. Makarova EV, Senchukova MA. Cervical cancer in the Orenburg region and the Russian Federation for 2007-2016. Orenburg Medical Bulletin. 2018;6(4;24):20–30. (In Russ).

20. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris. 2024. Available at: https://uroweb.org/guidelines/penile-cancer/chapter/citation-information. Accessed: 2 May 2024.

21. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12‐49. doi: 10.3322/caac.21820.

22. Mix JM, Van Dyne EA, Saraiya M, et al. Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15-29 Years in the United States, 1999-2017: An Ecologic Study. Cancer Epidemiol Biomarkers Prev. 2021;30(1):30–37. doi: 10.1158/1055-9965.EPI-20-0846.

23. Baandrup L, Maltesen T, Dehlendorff C, et al. Human papillomavirus vaccination and anal high-grade precancerous lesions and cancer—a real-world effectiveness study. JNCI: Journal of the National Cancer Institute. 2024;116(2):283–287. doi: 10.1093/jnci/djad189.

24. Elst L, Albersen M. HPV Vaccination: Does It Have a Role in Preventing Penile Cancer and Other Preneoplastic Lesions? Semin Oncol Nurs. 2022;38(3):151284. doi: 10.1016/j.soncn.2022.151284.